Nuvectis Pharma, Inc.

NasdaqCM:NVCT Stock Report

Market Cap: US$171.9m

Nuvectis Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:NVCT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
05 Nov 25BuyUS$75,270Juan SanchezIndividual13,000US$5.79
05 Nov 25BuyUS$64,240Matthew KaplanIndividual11,000US$5.84
05 Nov 25BuyUS$28,600Ron BentsurIndividual5,000US$5.72
27 Oct 25BuyUS$957,083Charles Mosseri-MarlioIndividual154,770US$6.28
20 Jun 25BuyUS$44,768Charles Mosseri-MarlioIndividual5,603US$7.99
18 Jun 25BuyUS$269,532Charles Mosseri-MarlioIndividual33,442US$8.11
12 May 25BuyUS$171,664Charles Mosseri-MarlioIndividual21,167US$8.11
09 May 25BuyUS$460,420Charles Mosseri-MarlioIndividual52,473US$8.99
07 Feb 25BuyUS$1,200,000Charles Mosseri-MarlioIndividual240,000US$5.00
24 Dec 24BuyUS$20,925Ron BentsurIndividual4,500US$4.65
13 Dec 24BuyUS$228,941Charles Mosseri-MarlioIndividual49,121US$4.70

Insider Trading Volume

Insider Buying: NVCT insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of NVCT?
Owner TypeNumber of SharesOwnership Percentage
Institutions4,005,47915.6%
Individual Insiders10,371,08540.5%
General Public11,238,33243.9%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 32.6%.

Top Shareholders

Top 25 shareholders own 54.72% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.5%
Ron Bentsur
3,455,924US$23.2m3.44%no data
12.7%
Charles Mosseri-Marlio
3,245,897US$21.8m5.01%no data
6.09%
Enrique Poradosu
1,559,652US$10.5m0%no data
6.04%
Shay Shemesh
1,546,401US$10.4m0%no data
2.73%
The Vanguard Group, Inc.
698,708US$4.7m4.78%no data
2.68%
BlackRock, Inc.
685,337US$4.6m6.59%no data
1.58%
Iridian Asset Management LLC
405,621US$2.7m8.83%0.99%
1.37%
Baldwin Wealth Partners, LLC
350,461US$2.4m0%0.15%
1.27%
Geode Capital Management, LLC
325,733US$2.2m14.2%no data
1.13%
Occam Crest Management LP
290,000US$1.9m0%1.42%
1.13%
Pontifax Venture Capital
288,873US$1.9m0%2.67%
0.54%
Michael Carson
138,918US$932.1k0%no data
0.53%
State Street Global Advisors, Inc.
136,716US$917.4k20.4%no data
0.52%
Kenneth Hoberman
133,140US$893.4k0%no data
0.49%
Matthew Kaplan
124,760US$837.1k9.67%no data
0.42%
Northern Trust Global Investments
106,641US$715.6k-2.89%no data
0.35%
Susquehanna International Group, LLP
90,879US$609.8k101%no data
0.34%
James Oliviero
87,828US$589.3k0%no data
0.31%
Juan Sanchez
78,565US$527.2k19.8%no data
0.27%
Oppenheimer Asset Management Inc.
69,066US$463.4k0%no data
0.23%
J.M. Forbes & Co. LLP
59,000US$395.9k0%0.03%
0.17%
Renaissance Technologies LLC
42,800US$287.2k-0.47%no data
0.15%
Charles Schwab Investment Management, Inc.
37,982US$254.9k0%no data
0.12%
RBC Dominion Securities Inc.
30,600US$205.3k37.9%no data
0.11%
BNY Asset Management
28,071US$188.4k3.05%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/08 07:55
End of Day Share Price 2025/12/05 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nuvectis Pharma, Inc. is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Aydin HuseynovLadenburg Thalmann & Company
I-Eh JenLaidlaw & Company (UK) Ltd